1stOncology™: Cancer Intelligence Service – Page 13297 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

BioCryst to Present at H.C. Wainwright Global Investment Conference

On September 3, 2019 BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) reported that the company will present at the H.C. Wainwright Global Investment Conference in New York on Monday, September 9, 2019 at 9:10 a.m. ET (Press release, BioCryst Pharmaceuticals, SEP 3, 2019, View Source [SID1234539186]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Links to a live audio webcast and replay of the presentation may be accessed in the Investors section of BioCryst’s website at http://www.biocryst.com.

ProMIS Neurosciences to Present at HC Wainwright Investor Conference

On September 3, 2019 ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, reported its participation in the 21st Annual Global Investment Conference sponsored by H.C. Wainwright & Co. LLC (Press release, ProMIS Neurosciences, SEP 3, 2019, View Source [SID1234539185]). The conference is being held September 8-10, 2019 at the New York Palace Hotel in New York.

ProMIS’ Executive Chairman, Eugene Williams will provide overviews of its novel drug discovery and development programs for Alzheimer’s disease, Parkinson’s disease and ALS (amyotrophic lateral sclerosis) Tuesday, September 10th at 10:25 am ET. The audio webcast and slides of Mr. Williams’ presentation will be archived and available on ProMIS’ web site and through the following link View Source

Macrophage Pharma Appoints Dr Søren Bregenholt as Chief Executive Officer

On September 3, 2019 Macrophage Pharma Limited (‘MPL’), a company focused on the discovery and development of next-generation immunomodulatory small molecules inducing transcriptional reprofiling of macrophages to combat cancer and other diseases, announced today that it has appointed Dr Soren Bregenholt as Chief Executive Officer (Press release, Macrophage Pharma, SEP 3, 2019, View Source [SID1234539184]).

Commenting on the appointment, Dr Michael Moore, Chairman of Macrophage Pharma, said: "The Board is delighted to have attracted Søren to Macrophage Pharma. Soren’s outstanding track record from executive positions in both biotech and pharma, as well as his extensive expertise and insight in immunology, will be invaluable as we further develop and commercialise our proprietary Esterase Sensitive Motif (ESM) platform and evolve Macrophage Pharma into a leading biotech company."

Dr Søren Bregenholt, CEO of Macrophage Pharma, said: "I am excited to join Macrophage Pharma as CEO. The Company’s unique and proprietary ESM technology platform is a compelling strategy for inducing transcriptional reprofiling of monocytes and macrophages and represents a differentiated approach to modulation of a centrally important regulator of the immune response across a variety of human diseases. I look forward to working with management and Board to unlock the full therapeutic and commercial potential of the technology in both cancer and non-cancer fields."

Søren Bregenholt PhD is a Danish national with an extensive operational and strategic track record from the biotech and pharmaceutical industries. He previously held senior executive roles including COO and CBO at Danish biotech companies Symphogen and IO Biotech, respectively. As part of the global R&D Management at Novo Nordisk, Søren was responsible for the global R&D Strategy and External Innovation efforts. Currently, Søren serves as Chairman of the Board at the Danish-Swedish life science organization Medicon Valley Alliance. His academic career, at the University of Copenhagen and Institute Pasteur, Paris, has focussed on immunoregulation and immunopathology in cancer and other diseases.

Akari Therapeutics to Participate in Citi and H.C. Wainwright Conferences in Early September

On September 3, 2019 Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene (LTB4) systems are implicated, reported that Clive Richardson, Chief Executive Officer, will participate and host investor meetings at the following September Conferences (Press release, Akari Therapeutics, SEP 3, 2019, https://www.akaritx.com/2019/09/03/akari-therapeutics-to-participate-in-citi-and-h-c-wainwright-conferences-in-early-september/ [SID1234539183]):

Citi’s 14th Annual Biotech Conference

Date: Wednesday, September 4, 2019

Place: Four Seasons, Boston, Mass.

H.C. Wainwright 21st Annual Global Investment Conference

Date: Tuesday, September 10, 2019

Place: Lotte New York Palace, New York City

Presentation Time: 12:30 p.m. ET

A live audio webcast of the H.C. Wainwright Conference presentation can be accessed by visiting ‘Events’ in the Investor Relations section on the Company’s website at www.akaritx.com. An archived replay of the webcast will be available for 60 days on the Company’s website after the conference.
Investors interested in arranging a meeting with the Company’s management during these two conferences should contact the respective conference coordinators.

Bristol-Myers Squibb to Take Part at the Morgan Stanley Conference

On September 3, 2019 Bristol-Myers Squibb Company (NYSE: BMY) reported that it will take part in a fireside chat at the Morgan Stanley Conference on Monday, September 9, 2019, in New York (Press release, Bristol-Myers Squibb, SEP 3, 2019, View Source [SID1234539182]). Giovanni Caforio, M.D., chairman and chief executive officer will answer questions at 4:15 p.m. ET.

Investors and the general public are invited to listen to a live webcast of the session at View Source Materials related to the presentation will be available at the same website at the start of the live webcast. An archived edition of the session will be available later that day.